
Caroline S. Fox
Boston
Articles
-
Jan 13, 2025 |
obgyn.onlinelibrary.wiley.com | Caroline S. Fox |Andrew H Shennan
Recently, the international company Hologic has withdrawn fetal fibronectin (fFN), a commonly used biomarker for preterm birth prediction. This is related to quality controls and sourcing consumables. However, fFN is currently recommended by the National Institute for Health and Care Excellence (NICE) and the National Health Service in England and had been implemented widely across Europe and the United Kingdom.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →